Pomotrelvir - Pardes Biosciences
Alternative Names: 6XHD59349R; PBI-0451Latest Information Update: 14 Jul 2023
Price :
$50 *
At a glance
- Originator Pardes Biosciences
- Class Antivirals
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 14 Jul 2023 Pomotrelvir - Pardes Biosciences is available for licensing as of 14 Jul 2023. https://www.pardesbio.com/lets-connect/ (Pardes Biosciences website, July 2023)
- 03 Apr 2023 Discontinued - Phase-I for COVID-2019 infections (In volunteers) in New Zealand (PO)
- 03 Apr 2023 Discontinued - Phase-II for COVID-2019 infections (In adults) in USA (PO)